5,421 Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 133,935 shares of the biopharmaceutical company’s stock after purchasing an additional 5,421 shares during the period. ProShare Advisors LLC owned about 0.10% of Alnylam Pharmaceuticals worth $33,047,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $278,321,000. Bank of New York Mellon Corp bought a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $148,128,000. Canada Pension Plan Investment Board bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $100,618,000. Korea Investment CORP acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $74,553,000. Finally, Wellington Management Group LLP boosted its stake in shares of Alnylam Pharmaceuticals by 9.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock valued at $635,296,000 after purchasing an additional 174,482 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $165.00 on Monday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $163.30 and a 12 month high of $479.79. The firm has a fifty day simple moving average of $236.49 and a 200 day simple moving average of $286.19. The stock has a market capitalization of $22.10 billion, a price-to-earnings ratio of 8.57 and a beta of 0.43. The company has a current ratio of 2.48, a quick ratio of 2.43 and a debt-to-equity ratio of 0.18.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a return on equity of 155.33% and a net margin of 52.85%. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the previous year, the business earned $2.90 earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.58 EPS for the current fiscal year.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
• Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
• Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
• Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
• Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Barclays cut their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Royal Bank Of Canada cut their price target on shares of Alnylam Pharmaceuticals from $345.00 to $280.00 and set an “outperform” rating on the stock in a research report on Friday. Raymond James Financial cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and decreased their price objective for the company from $420.00 to $315.00 in a report on Friday. Wells Fargo & Company cut their target price on shares of Alnylam Pharmaceuticals from $253.00 to $220.00 and set an “equal weight” rating on the stock in a report on Friday. Finally, Truist Financial decreased their price target on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $317.95.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.